论文部分内容阅读
目的:探析胃癌临床诊断时应用肿瘤标志物联合检验的临床价值.方法:选择我院确诊为胃癌患者100例纳入到观察组,以诊断为胃部良性病变患者100例作为对照组,以来院进行体检的健康人员100例作为参照组,三组纳入时间均为时间为2020年5月至2021年5月,均抽取静脉血检测肿瘤标志物,记录三组患者的CEA、CA242、CA199、CA721四项指标水平,分析四项肿瘤标志物联合检验结果.结果:相比于观察组胃癌患者恶言,对照组与参照组的CEA、CA242、CA199、CA721四项指标水平明显降低,比较差异明显(P＜“,”Objective: To explore the clinical value of tumor marker combined test in the clinical diagnosis of gastric cancer. Methods: A total of 100 patients diagnosed with gastric cancer in our hospital were included in the observation group, 100 patients diagnosed with gastric benign lesions were taken as the control group, and 100 healthy people who underwent physical examination in our hospital were taken as the reference group. The inclusion time of the three groups was from May 2020 to May 2021, and venous blood was collected to detect tumor markers. CEA, CA242, CA199 and CA721 of patients in the three groups were recorded, and the results of the combined test of the four tumor markers were analyzed. Results: Compared with the observation group, the levels of CEA, CA242, CA199 and CA721 in the control group and the reference group were significantly decreased, with significant differences (P＜0.05). Compared with single detection, combined detection has a higher accuracy in the diagnosis of gastric cancer, and can distinguish the stage and differentiation degree of gastric cancer patients, and know whether there is liver metastasis. Conclusions: Gastric cancer patients receiving CEA, CA242, CA199, CA721 tumor markers combined test, higher diagnostic accuracy, can accurately analyze the condition of patients with gastric cancer, better guide the clinical diagnosis and treatment work.